172 related articles for article (PubMed ID: 24444014)
1. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Zhou S
Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
3. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS; Long SB; Beese LS
Biochemistry; 2004 Jul; 43(28):9000-8. PubMed ID: 15248757
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
5. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
6. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Appels NM; Bolijn MJ; van Eijndhoven MA; Stephens TC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):137-45. PubMed ID: 20229082
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
Roskoski R; Ritchie PA
Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
Kim KW; Chung HH; Chung CW; Kim IK; Miura M; Wang S; Zhu H; Moon KD; Rha GB; Park JH; Jo DG; Woo HN; Song YH; Kim BJ; Yuan J; Jung YK
Oncogene; 2001 Jan; 20(3):358-66. PubMed ID: 11313965
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
Rehni AK; Singh TG
Neuropharmacology; 2013 Aug; 71():19-26. PubMed ID: 23415632
[TBL] [Abstract][Full Text] [Related]
11. Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I.
Zhang FL; Casey PJ
Biochem J; 1996 Dec; 320 ( Pt 3)(Pt 3):925-32. PubMed ID: 9003382
[TBL] [Abstract][Full Text] [Related]
12. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
Curtin ML; Florjancic AS; Cohen J; Gu WZ; Frost DJ; Muchmore SW; Sham HL
Bioorg Med Chem Lett; 2003 Apr; 13(7):1367-71. PubMed ID: 12657284
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS; Beese LS
Biochemistry; 2004 Jun; 43(22):6877-84. PubMed ID: 15170324
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I.
Del Villar K; Mitsuzawa H; Yang W; Sattler I; Tamanoi F
J Biol Chem; 1997 Jan; 272(1):680-7. PubMed ID: 8995312
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
17. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
Caplin BE; Ohya Y; Marshall MS
J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
[TBL] [Abstract][Full Text] [Related]
18. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
19. Targeted reengineering of protein geranylgeranyltransferase type I selectivity functionally implicates active-site residues in protein-substrate recognition.
Gangopadhyay SA; Losito EL; Hougland JL
Biochemistry; 2014 Jan; 53(2):434-46. PubMed ID: 24344934
[TBL] [Abstract][Full Text] [Related]
20. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
Peterson YK; Kelly P; Weinbaum CA; Casey PJ
J Biol Chem; 2006 May; 281(18):12445-50. PubMed ID: 16517596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
